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ABSTRACT
Resistance to chemotherapy is one of the leading causes of death from breast 
cancer. We recently established that loss of Adenomatous Polyposis Coli (APC) in 
the Mouse Mammary Tumor Virus – Polyoma middle T (MMTV-PyMT) transgenic 
mouse model results in resistance to cisplatin or doxorubicin-induced apoptosis. 
Herein, we aim to establish the mechanism that is responsible for APC-mediated 
chemotherapeutic resistance. Our data demonstrate that MMTV-PyMT;ApcMin/+ cells 
have increased signal transducer and activator of transcription 3 (STAT3) activation. 
STAT3 can be constitutively activated in breast cancer, maintains the tumor initiating 
cell (TIC) population, and upregulates multidrug resistance protein 1 (MDR1). The 
activation of STAT3 in the MMTV-PyMT;ApcMin/+ model is independent of interleukin 
6 (IL-6); however, enhanced EGFR expression in the MMTV-PyMT;ApcMin/+ cells may 
be responsible for the increased STAT3 activation. Inhibiting STAT3 with a small 
molecule inhibitor A69 in combination with doxorubicin, but not cisplatin, restores 
drug sensitivity. A69 also decreases doxorubicin enhanced MDR1 gene expression 
and the TIC population enhanced by loss of APC. In summary, these results have 
revealed the molecular mechanisms of APC loss in breast cancer that can guide future 
treatment plans to counteract chemotherapeutic resistance.
INTRODUCTION
Breast cancer is the most commonly diagnosed cancer 
in women in the United States [1]. Despite the high rate 
of diagnosis and early detection, breast cancer is still the 
2nd leading cause of cancer death in women in the United 
States [1]. One of the primary contributors to poor prognosis 
in breast cancer patients is chemotherapeutic resistance. 
Although the exact mechanisms leading to chemotherapeutic 
resistance have not been fully elucidated, it is known that 
molecular changes that affect signaling pathways can impact 
chemotherapeutic resistance. Chemotherapeutic resistance 
can be intrinsic or acquired and a number of cell signaling 
pathways can lead to resistance (reviewed by [2]). For 
our studies, we are focused on intrinsic chemotherapeutic 
resistance and determining the signaling pathways that are 
involved in this resistance. Although a number of theories 
have been proposed (reviewed by [3]), the most common 
cause of chemotherapeutic resistance is multidrug resistance 
driven by alterations in gene expression for ATP binding 
cassette efflux pumps (ABC transporters), which affect the 
rate of drug efflux from the tumor cells. Therefore, increased 
pump expression results in tumor cells being less responsive 
to chemotherapeutic agents. 
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Chemotherapy is often used to treat a variety of 
breast cancer subtypes either in a neoadjuvant or adjuvant 
fashion. The drugs used can vary and are often given in 
combination with different classes of chemotherapeutic 
agents. Doxorubicin alone or in combination with other 
chemotherapeutic agents is one of the most common 
treatments for women with triple negative breast cancer 
[4]. Cisplatin is also used to treat triple negative breast 
cancer [5, 6]. Our work focuses on determining the 
mechanism(s) involved in cisplatin and doxorubicin 
resistance incurred from loss of APC. Doxorubicin is an 
anthracyline that intercalates into the DNA and prevents 
cellular replication [7], whereas cisplatin is a platinum-
based drug that forms DNA adducts (reviewed in [6]). 
Loss of Adenomatous Polyposis Coli (APC) through 
mutation or hypermethylation occurs in up to 70% of 
sporadic breast cancer patients [8–10]. We previously 
reported that heterozygous Apc mutation in the Mouse 
Mammary Tumor Virus – Polyoma middle T (MMTV-
PyMT) transgenic mouse model leads to enhanced 
tumorigenesis [11]. Based on the interaction of APC with 
its binding partners, we assessed the cellular response to 
cisplatin, paclitaxel, and doxorubicin [12], and we made 
the novel observation that APC loss led to doxorubicin 
and cisplatin resistance. Therefore, we focused on the 
effects of doxorubicin and cisplatin for these studies. Cells 
isolated from these tumors have increased expression 
of multidrug resistance protein 1 (MDR1) and tumor 
initiating cell (TIC) populations that may be responsible 
for the resistance to cisplatin or doxorubicin-mediated 
apoptosis [12]. Knowledge of the potential mechanism 
of APC-mediated chemotherapeutic resistance can be 
used to develop combination treatments to overcome this 
resistance. We previously demonstrated that synergism 
between cisplatin and Src or JNK inhibition restored 
cisplatin sensitivity in the MMTV-PyMT;ApcMin/+ cells; 
however, the same relationship was not evident with 
doxorubicin [12]. While doxorubicin treatment was not 
impacted by Src or JNK inhibition, doxorubicin enhanced 
MDR1 gene expression in MMTV-PyMT;ApcMin/+ cells 
[12]. These data point to divergent mechanisms of action 
between cisplatin and doxorubicin resistance in the 
absence of APC.
Signal transducer and activator of transcription 3 
(STAT3) is a potential modulator of chemotherapeutic 
resistance in the model of APC loss in breast cancer. 
STAT3 is constitutively activated in triple negative breast 
cancer tissues and cells lines and helps maintain the 
population of TICs [13]. TICs have higher levels of ABC 
transporters including MDR1 compared to normal cells 
and can impact chemotherapeutic resistance [14]. TICs 
can be identified by over-expression of activated STAT3 
[15, 16]. STAT3 can upregulate MDR1 gene expression 
as well [17–19]. Our data indicate that doxorubicin 
resistance may occur through MDR1 since MDR1 
expression is augmented by treatment with doxorubicin 
in MMTV-PyMT;ApcMin/+ cells [12]. Doxorubicin is 
one chemotherapeutic agent that is effluxed by MDR1 
(reviewed by [20]).
Understanding the molecular mechanisms 
downstream of APC loss in breast cancer will be important 
in future treatment plans, especially the development of 
individualized treatment plans. Patients can become resistant 
to many of the commonly used chemotherapeutic agents. 
We report here that inhibition of STAT3 with the small 
molecule inhibitor, A69, restores sensitivity to doxorubicin, 
but not cisplatin, in MMTV-PyMT;ApcMin/+ cells.
RESULTS
We previously demonstrated that loss of APC in 
the MMTV-PyMT mouse model results in resistance to 
cisplatin and doxorubicin-induced apoptosis, increased 
MDR1 expression, and increased the TIC population 
[12]. Given that increased MDR1 and TICs are known 
mechanisms of chemotherapeutic resistance and are 
impacted by STAT3 activation, we sought to determine 
whether STAT3 was involved in APC-mediated 
chemotherapeutic resistance. The MMTV-PyMT;ApcMin/+ 
cells have increased levels of phosphorylated STAT3 
(pSTAT3) protein, with no difference in total STAT3 
(Figure 1A and 1B). The functionality of the increased 
pSTAT3 was confirmed using a dual-luciferase reporter 
assay to show that MMTV-PyMT;ApcMin/+ cells have 
increased transcriptional activity of STAT3 (Figure 1C). 
We sought to understand how APC loss results in aberrant 
STAT3 activation. As STAT3 is often activated through 
IL-6 dependent pathways [13, 21, 22], we used a mouse 
specific IL-6 ELISA and demonstrated no difference in 
IL-6 production between the two cell lines (Figure 1D). 
In addition to IL-6-mediated STAT3 phosphorylation, 
aberrant EGFR signaling can also increase STAT3 
activation [23, 24]. Investigation of EGFR demonstrated 
that MMTV-PyMT;ApcMin/+ cells have increased EGFR 
expression (Figure 1E and 1F), suggesting this as a 
possible link between APC loss and STAT3 activation. 
Based on these data, we speculate that EGFR, not IL6, 
is responsible for STAT3 activation in the MMTV-
PyMT;ApcMin/+ cells. To understand how hyperactivation of 
STAT3 may impact chemoresistance, we looked at genes 
under transcriptional control by STAT3, including Mcl-1 
and Bcl-2, which are pro-survival proteins in the apoptosis 
cascade. Given the impact of APC loss on the apoptotic 
response after chemotherapy treatment, Bcl-2 and Mcl-1 
protein levels were assessed. We show that the MMTV-
PyMT;ApcMin/+ cells have increased expression of Bcl-2 
(Figure 1G and 1H), but not Mcl-1 (Figure 1G and 1I).
Next, we aimed to understand how treatment with 
cisplatin and doxorubicin affects activation of STAT3 to 
determine whether this would impact chemotherapeutic 
resistance. Cisplatin treatment for 24 hours significantly 
decreased pSTAT3 in both cell lines (Figure 2A and 2B). 
Oncotarget102870www.impactjournals.com/oncotarget
Doxorubicin also slightly decreased pSTAT3 expression 
selectively in the MMTV-PyMT;ApcMin/+ cells (Figure 2A 
and 2B). Similar results were obtained with the STAT3 
reporter assay confirming a loss of STAT3 transcriptional 
activity after cisplatin treatment in both cell lines (Figure 
2C). Treatment with chemotherapeutic agents had no 
effect on Bcl-2 protein expression (Figure 2D and 2E). 
Interestingly, cisplatin treatment, and doxorubicin to a lesser 
extent, for 24 hours decreased Mcl-1 protein expression 
similar to the effect on pSTAT3 (Figure 2D and 2F). 
Recently, a group of selective small molecule 
inhibitors targeting the DNA-binding domain of STAT3 
has been identified and shown to inhibit cell proliferation 
and migration in vitro and tumor development in vivo [25, 
26]. Here, we used one of these STAT3 inhibitors, A69, 
to determine the impact of STAT3 inhibition on growth 
of MMTV-PyMT;ApcMin/+  and MMTV-PyMT;Apc+/+ 
cells. Initial concentrations of A69 were determined 
based on previous studies in multiple cell lines [25, 26]. 
Cell growth assays determined that A69 (10 μM for 24 
Figure 1: Loss of APC leads to increased activation of STAT3. (A) Western blot analysis demonstrates that MMTV-PyMT;ApcMin/+ 
cells have increased pSTAT3 but similar levels of total STAT3. (B) Quantification of pSTAT3/STAT3 in MMTV-PyMT;ApcMin/+ vs MMTV-
PyMT;Apc+/+ cells shows a significant increase in activated STAT3. (C) Western blot results were confirmed using a dual luciferase reporter 
assay. Cells were transfected with STAT3 and pRL-TK reporter plasmids for 24 hours and luciferase activity was measured. (D) IL-6 
production was measured in media using ELISA, and no difference was observed between MMTV-PyMT;Apc+/+ and MMTV-PyMT;ApcMin/+ 
cells. (E) Representative western blots for total EGFR show an increase in MMTV-PyMT;ApcMin/+ compared to MMTV-PyMT;Apc+/+ cells. 
(F) Quantification of EGFR normalized to actin shows that MMTV-PyMT;ApcMin/+ cells express higher levels of EGFR compared to 
MMTV-PyMT;Apc+/+ cells. (G) Representative western blots for the anti-apoptotic proteins, Bcl-2 and Mcl-1, and quantification (H) shows 
that Bcl-2 is increased in MMTV-PyMT;ApcMin/+ cells compared to MMTV-PyMT;Apc+/+ cells, while Mcl-1 (I) is unchanged. Actin was 
used as a loading control for all western blot experiments. Each experiment was repeated 3 times and data are shown as means +/- SD; *P 
< 0.05 comparing MMTV-PyMT;ApcMin/+ to MMTV-PyMT;Apc+/+ cells.
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hours) was effective in reducing cell numbers by 40–50% 
(Figure 3A). Western blot analysis demonstrated that A69 
(10 uM) resulted in a slight decrease in STAT3 activation 
at 24 hours (Figure 3B and 3C). To understand whether 
the STAT3 activity was directly responsible for Bcl-2 and 
Mcl-1, we performed western blots on cell lysates treated 
with A69 for 24 hours. Treatment with A69 for 24 hours 
had no effect on Bcl-2 or Mcl-1 protein expression (Figure 
3D–3F).
Given that we previously demonstrated that 
MMTV-PyMT;ApcMin/+ cells were resistant to cisplatin and 
doxorubicin [12], we next wanted to understand whether 
inhibiting STAT3 would restore the apoptotic response. 
Using cleaved caspase 3 (CC3) immunofluorescence 
(IF), we showed that A69 alone does not induce a robust 
increase in apoptosis (Figure 4A and 4B). A69 sensitized 
MMTV-PyMT;ApcMin/+ cells to doxorubicin (Figure 4A and 
4B), but had no impact on the response to cisplatin in the 
MMTV-PyMT;ApcMin/+ cells (Figure 4B). The combination 
of doxorubicin and A69 synergistically increased the 
apoptotic response in the MMTV-PyMT;ApcMin/+ cells 
(Figure 4A and 4B, p < 0.0001). These data indicate 
that STAT3 inhibition specifically restores sensitivity to 
doxorubicin in the MMTV-PyMT;ApcMin/+ cells.   
To further investigate how increased activation of 
STAT3 results in doxorubicin resistance in the MMTV-
PyMT;ApcMin/+ cells, we  focused the remainder of our 
studies on STAT3-induced MDR1 and TIC population. 
Based on the links between STAT3 and these two pathways 
[19], and having previously made the observation that 
Figure 2: Chemotherapeutic treatments affect activation of STAT3. (A) Representative western blots showing the changes 
in pSTAT3 and STAT3 in MMTV-PyMT;ApcMin/+ vs MMTV-PyMT;Apc+/+ cells treated with cisplatin or doxorubicin for 24 hours. (B) 
Quantification of westerns blots shows that cisplatin nearly eliminates pSTAT3 in both cell lines. (C) Dual luciferase reporter assays measured 
STAT3 activation after treatment with cisplatin and doxorubicin and confirmed that cisplatin decreased STAT3 activity in both cells lines. (D) 
Representative western blots for Mcl-1 and Bcl-2 after 24-hour treatment with cisplatin and doxorubicin. (E) Quantification of western blots 
shows that chemotherapeutic agents do not affect Bcl-2 at the protein level. (F) Western blot quantification demonstrates that both cisplatin 
and doxorubicin decrease Mcl-1 in MMTV-PyMT;ApcMin/+ cells. Each experiment was repeated 3 times and data are shown as means +/- SD; 
*P < 0.05 compared to solvent control, **P < 0.05 comparing MMTV-PyMT;ApcMin/+ to MMTV-PyMT;Apc+/+ cells
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MMTV-PyMT;ApcMin/+ cells have increased MDR1 
expression that is enhanced by treatment with doxorubicin 
[12], we performed qRT-PCR to determine the effect of 
A69 on MDR1 gene expression in MMTV-PyMT;ApcMin/+ 
cells.  While we found no effect of A69 alone, when 
treated in combination with doxorubicin, A69 blocked 
the ability of doxorubicin to increase MDR1 expression 
(Figure 5A). There were no effects of A69 on MDR1 gene 
expression in the MMTV-PyMT;Apc+/+ cells (data not 
shown and [12]). To understand the relationship between 
the increased activation of STAT3 and the increased TIC 
population that we observed in the MMTV-PyMT;ApcMin/+ 
cells [12], Aldefluor assays were performed. As expected, 
there was no effect of A69 on the TIC population of the 
MMTV-PyMT;Apc+/+ cells. A69 treatment significantly 
decreased the TIC population in the MMTV-PyMT;ApcMin/+ 
cells (Figure 5B and 5C). However, the TIC population 
was not reduced to that of the MMTV-PyMT;Apc+/+ cells, 
suggesting that STAT3 acts in combination with other 
signaling modalities to enhance the TIC population. 
DISCUSSION 
We have previously demonstrated that loss of 
APC in the MMTV-PyMT mouse transgenic model 
results in resistance to both cisplatin and doxorubicin 
that is independent of Wnt/β-catenin activation [12]. The 
molecular mechanisms resulting in chemotherapeutic 
resistance mediated by APC loss are not well understood. 
We have established a potential pathway that can be 
targeted in breast cancer patients to restore sensitivity 
to doxorubicin. Loss of APC in the MMTV-PyMT 
mouse model increases activation of STAT3, which is 
constitutively activated in approximately 50% of breast 
cancer cell lines and tumor samples [13]. 
We used Mcl-1 and Bcl-2 expression as an indicator 
of downstream activity of STAT3 since both proteins are 
involved in the apoptotic response. Inhibition of STAT3 
by both curcumin and its analogue hydrazinocurcumin 
blocks protein expression of both Mcl-1 and Bcl-2 in 
MDA-MB-231 and MCF-7 breast cancer cells [27]. 
Figure 3: STAT3 inhibition in MMTV-PyMT;ApcMin/+ and MMTV-PyMT;Apc+/+ cells. (A) Cell growth was measured for 24 
hours with treatment 0–20 μM A69, a small molecule inhibitor of STAT3. Data are shown as the percent of cells compared to the untreated 
control (set to 100% for each cell line individually). (B) Representative western blots for pSTAT3/STAT3 after treatment with 0–10 μM of 
A69 for 24 hours. (C) Quantification of pSTAT3/STAT3 western blots show that 10 μM modestly decreases STAT3 phosphorylation in both 
cell lines. 10 μM was selected as the dose for A69 for future studies. (D) Representative western blots for Mcl-1 and Bcl-2 after 24-hour 
treatment with 10 μM A69. (E–F) Quantification of Bcl-2 and Mcl-1 western blots demonstrates that A69 does not affect Bcl-2 or Mcl-1 
expression. Each experiment was repeated at least 3 times and data are shown as means +/- SD; *P < 0.05 compared to solvent control, **P 
< 0.05 comparing MMTV-PyMT; ApcMin/+ to MMTV-PyMT; Apc+/+ cells. 
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Although we did not note a difference in Mcl-1 or Bcl-
2 protein expression after treatment with A69, this may 
be due to alternate components of the STAT3 signaling 
pathway. We also showed that treatment with cisplatin 
reduces Mcl-1 expression, which may be due to the loss 
of STAT3 activation. These results are similar to those in 
renal tubular epithelial cells where treatment with cisplatin 
affected Mcl-1 expression but not Bcl-2 expression [28].  
Since inhibition of STAT3 restores sensitivity to 
doxorubicin in the MMTV-PyMT;ApcMin/+ mouse model, 
we were interested in understanding how this restoration 
occurred. We focused on two specific mechanisms, MDR1 
expression and TIC population, that we have shown to 
possibly be involved in chemotherapeutic resistance in 
the MMTV-PyMT;ApcMin/+ cells [12]. Others have also 
demonstrated that inhibition of STAT3 decreases the 
TIC population in breast cancer cells [15]. A69 reduced 
the TIC population in MMTV-PyMT;ApcMin/+ cells but 
did not restore levels to that of the MMTV-PyMT;Apc+/+ 
cells, suggesting alternate factors associated with Apc loss 
that enhance the TIC population. A number of signaling 
pathways besides STAT3 can enhance TICs in breast cancer 
including NOTCH signaling, Hedgehog signaling, and 
integrins (reviewed in [29]). We also found that A69 prevents 
doxorubicin from enhancing MDR1 gene expression, which 
may be responsible for the intrinsic doxorubicin resistance 
observed in the MMTV-PyMT;ApcMin/+ cells. As cisplatin 
is not effluxed by MDR1 [20], we hypothesize this is the 
primary reason A69 could not restore cisplatin sensitivity. 
Interestingly, STAT3 can also play a role in modulating 
DNA damage pathways [30], which could contribute to 
the STAT3-mediated doxorubicin resistance in MMTV-
PyMT;ApcMin/+ cells. The role of STAT3 in DNA damage 
has been highlighted in fibrosarcoma, where cells with low 
STAT3 levels have decreased ATM-Chk1 and ATM-Chk2 
via transcriptional regulation of MDC1 [30]. 
Figure 4: Effects of chemotherapeutic agents on apoptosis. (A) Representative immunofluorescence (IF) images for MMTV-
PyMT;ApcMin/+ cells treated with A69, doxorubicin, or the combination of A69 and doxorubicin. White arrows depict cleaved caspase 3 
(CC3) positive cells, and the scale bar is 200 μM. (B) Quantification of the percent of CC3 positive cells after 24-hour treatment with single 
agents or combination of A69 with either cisplatin or doxorubicin. A69 alone does not cause a significant increase in apoptosis. Treatment 
with A69 in combination with doxorubicin restores sensitivity in MMTV-PyMT;ApcMin/+ cells. The experiment was repeated 3 times, at least 
150 cells were counted per condition in each experiment, and data are shown as means +/- SD; *P < 0.05 when compared to solvent control, 
**P < 0.05 comparing MMTV-PyMT;ApcMin/+ to MMTV-PyMT;Apc+/+ cells.
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Figure 5: Effects of A69 on MDR1 gene expression and the TIC population. (A) The doxorubicin-induced MDR1 gene 
expression in MMTV-PyMT;ApcMin/+ cells is inhibited by A69. Expression is normalized to 18s rRNA. (B) Representative FACS analysis 
of MMTV-PyMT;ApcMin/+ cells treated with solvent control or A69. (C) Quantification of Aldefluor assay in MMTV-PyMT;ApcMin/+ and 
MMTV-PyMT;Apc+/+ cells treated with solvent control or A69. Data are shown as the shift in gated events between test and control samples. 
Control samples were treated with an inhibitor DEAB. Each experiment was repeated 3 times and data are shown as means +/- SD; *P < 
0.05 compared to solvent control, **P < 0.05 when comparing MMTV-PyMT;ApcMin/+ vs MMTV-PyMT;Apc+/+ cells.
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Our initial hypothesis aimed to understand whether 
IL-6 was responsible for APC-mediated STAT3 activation. 
IL-6 commonly activates STAT3 in breast cancer models 
(reviewed in [31, 32]). IL-6 can be produced in an 
autocrine fashion in both breast [17], and ovarian [33], 
cancer and therefore is an important step in tumorigenesis 
(reviewed in [32]). Our results demonstrated that IL-6 is 
not responsible for the activation of STAT3 in MMTV-
PyMT;ApcMin/+ cells. In addition to IL-6, STAT3 can be 
activated by EGFR in many cancer types (reviewed in 
[31]). There is also a strong association between nuclear 
STAT3 and EGFR expression in breast cancer samples and 
this EGFR/STAT3 relationship enhances tumorigenesis 
[34]. STAT3 is also an important player in the cross-
talk that occurs with EGFR signaling [35]. Studies in 
Drosophila show that loss of Apc leads to activation of 
both STAT3 and EGFR [36]. In ApcMin/+ mice there is 
increased EGFR activity, demonstrating that the increased 
EGFR expression observed here may be directly linked 
to mutant Apc [37]. Previous literature demonstrated 
that EGFR recycling could be impacted by cell stress, 
suggesting a possible link between APC-mediated aberrant 
signaling and EGFR recycling [38]. Future work will 
dissect how APC loss leads to increased EGFR expression, 
focusing on specific post-translational modifications and 
the recruitment and recycling of EGFR. 
Chemotherapeutic resistance can also be caused by 
evading apoptosis and changing DNA repair mechanisms 
[3]. Future work will focus on these pathways as potential 
targets for resolving APC-mediated cisplatin resistance. 
We found that cisplatin treatment decreased activation of 
STAT3; however, this did not lead to cell death indicating 
activation of other signaling pathways allowing the MMTV-
PyMT;ApcMin/+ cells to evade cisplatin-induced apoptosis. 
Previously, we showed that combination treatments with 
inhibitors for JNK (SP600125) and Src (PP2) restore 
sensitivity of MMTV-PyMT;ApcMin/+ cells to cisplatin [12]. 
Thus future work will also delineate how these pathways are 
involved in APC-mediated cisplatin resistance. 
In conclusion, our results demonstrate that the 
STAT3 signaling pathway is important in the development 
of APC-mediated doxorubicin resistance but not cisplatin 
resistance. The effects may be due to EGFR upstream 
of STAT3 or changes in MDR1 and the TIC population 
downstream of STAT3 (Figure 6). These results will need 
to be confirmed using in vivo mouse models and may lead 
to promising combination treatments to overcome APC-
mediated doxorubicin resistance.
MATERIALS AND METHODS
Cell culture and drug treatment 
MMTV-PyMT;Apc+/+ and MMTV-PyMT;ApcMin/+ 
cells were isolated from primary tumors from the mouse 
mammary gland [11] and grown in RPMI 1640 media 
supplemented with 10% fetal bovine serum, 1% penicillin/
streptomycin, and 1:5000 plasmocin (Invivogen, San 
Diego, CA). All cells were routinely passaged using 
0.25% trypsin/EDTA and maintained at 37οC with 5% 
CO2. Experiments were performed with cells between 
passage 10–20. Cells were treated for 24 hours with each 
chemotherapeutic agent or solvent control: doxorubicin 
(500 nM MP Biomedicals, LLC, Santa Ana, CA) or 
cisplatin (16 μM; cis-Diammineplatinum (III) dichloride, 
Sigma-Aldrich) as described previously [12]. STAT3 DNA 
binding was blocked by 24-hour treatment with the small 
molecule inhibitor A69 [25, 26]. 
Cell growth assays 
50,000 cells were plated per well in 24-well plates 
in duplicate. 24 hours later cells were treated with 0–20 
μM A69. 24 hours post-treatment, adherent cells were 
trypsinized and counted. Data are normalized to the 
solvent control for each cell line.
Western blots 
Total protein was isolated using a phosphatase 
inhibitor enhanced lysis buffer (20 mM Tris-HCl, 150 
mM NaCl, 1% Triton-X, 0.5% NP-40, 50 mM NaF, 1 mM 
Na3VO4, 5 mM Sodium pyrophosphate, 0.2 mM PMSF, 
1x protease inhibitor cocktail (Fisher), and 1x phosphatase 
inhibitor cocktail 2 (Sigma)). Protein concentration was 
measured using a BCA assay. 20–25 µg of protein was 
separated by SDS-PAGE (10% gel), and transferred 
onto Immobilon-P membrane (Millipore). Following 
protein transfer, membranes were blocked for 1 hour at 
room temperature in 5% non-fat dry milk in 1XTBS with 
0.1% Tween (TBS-T). Blots were incubated with primary 
antibody diluted 1:1000 in 1% bovine serum albumin in 
TBS-T overnight at 4οC: STAT3 (#12640, Cell Signaling), 
pSTAT3 (#9145, Tyrosine 705, Cell Signaling), Mcl-
1 (#5453, Cell Signaling) Bcl-2 (#2870, Cell signaling) 
or EGFR (#4267, Cell Signaling). Membranes were 
incubated in secondary antibody (anti-rabbit IgG-HRP, 
1:1000 in 1% bovine serum albumin in TBS-T) at room 
temperature for 1 hour. Blots were developed with Clarity 
ECL reagent (Bio-Rad) and a ChemiDoc MP Imaging 
System (Bio-Rad). Blots were reprobed for β-actin 
(1:25,000, 1% BSA in TBS-T, Sigma) for 1 hour at room 
temperature followed by anti-mouse IgG-HRP (1:2000 in 
1% bovine serum albumin in TBS-T) for 1 hour at room 
temperature to verify equal protein loading. Densitometry 
quantification was performed using ImageJ software 
(NIH). Blots are representative of three replicates.
Reporter assays
 75,000 cells were plated in 24 well plates in 
triplicate and 24 hours later cells were transfected with 
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lipofectamine 2000 (6 µl, Life Technologies) and 6 µg of 
STAT3 Plasmid (Promega; pGL4.47(luc2P/SIE/Hygro)) 
and pRL-TK (for transfection efficiency, Promega). When 
cells were also treated with chemotherapeutic agents, 
treatments were done at the time of transfection. After 
24 hours, lysates were collected and luciferase activity 
was measured using the Dual Luciferase Assay Kits 
(Promega) according to manufacturer’s recommendations. 
A SpectraMax M3 plate reader (Molecular Devices, 
Sunnyvale, CA) was used to measure luciferase activity. 
We normalized firefly luciferase values to renilla luciferase 
values to account for differences in cell transfection.
Immunofluorescence
 Apoptosis was determined using cleaved caspase 3 
IF as previously described [12]. Briefly 40,000 cells were 
seeded in 12 well plates on glass coverslips in triplicate. 
24 hours later cells were treated with chemotherapeutic 
agents with or without A69 for 24 hours. After treatment, 
cells were fixed in 3.7% formaldehyde for 15 minutes 
and permeabilized in 0.3% Triton X-100 for 15 minutes. 
Antibodies were diluted in blocking buffer that consisted 
of 0.2% non-fat dry milk, 2% Bovine Serum Albumin and 
0.3% Triton X-100 in phosphate buffered saline (PBS). 
Primary anti-cleaved caspase 3 rabbit monoclonal antibody 
(1:400, Cell Signaling Technology, Danvers, MA) was 
applied to cells for 1 hour at 37οC. Following washes in 
PBS, samples were incubated in goat-anti-rabbit Alexa 
Fluor 488 (1:1000, Life Technologies, Carlsbad, CA) and 
Alexa 555 conjugated Phalloidin (1:200, Life Technologies) 
to visualize F-actin. Slides were mounted with Fluoromount 
G with Hoescht (Sigma) to label cell nuclei. The percentage 
of positive cells was determined for each assay with at least 
150 cells being counted per condition using the counting 
feature on an Evos Xl core microscope. Each assay was 
Figure 6: Schematic of APC-mediated doxorubicin resistance. Predicted model of how APC loss results in resistance to 
doxorubicin. We have shown that APC loss increases the phosphorylation of EGFR and STAT3. In addition, blocking STAT3 with A69 
blocks the APC-mediated effects on MDR1 expression and the TIC population. Finally, A69 is able to restore sensitivity to doxorubicin in 
the ApcMin/+ cells. The dashed line from EGFR to STAT3 indicates a potential regulation that we are currently investigating. The dashed line 
from “loss of APC” to STAT3 suggests that there may be other signaling modalities that we have yet to uncover. 
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run in triplicate and repeated three times. Representative 
images were taken on Zeiss Axio A1 Microscope with an 
AxioCam MRc digital camera.
RNA isolation and RT-PCR
MMTV-PyMT;Apc+/+ and MMTV-PyMT;ApcMin/+ 
cells were seeded at 8×105 cells per 10 cm plate for 
24 hours then treated with chemotherapy drugs and/or 
A69 as above for 24 hours. RNA was isolated using Tri 
Reagent (Molecular Research Center, Cincinnati, OH). 
cDNA synthesis was performed with iScript from 1 μg 
total RNA (Bio-Rad Laboratories, Hercules, CA). Real-
time RT-PCR was performed using Power SYBR Green 
master mix (Applied Biosystems, Foster City, CA), 50 
ng of cDNA, and 7.5 µM (or 3.75 µM for 18s) of each 
primer. Primers were the same as used previously for 
18s rRNA (reference gene) and MDR1 [12]. Primers 
were 18s F 5′-GGCGGCTTGGTGACTCTAGAT-3’, 
18s R 5′-CTTCCTTGGATGTGGTAGCCG-3’ MDR1 
F 5′-CATTGGTGTGGTGAGTCAGC-3’, MDR1 R 
5′-CTCTCTCTCCAACCAGGGTC-3’. The amplification 
program included 2 initial steps at 50ο C for 2 minutes and 
95ο C for 10 minutes followed by 40 cycles of 95ο C for 
15 seconds and 60οC for 1 minute followed by generation 
of a melt curve (CFX Connect 96 thermal cycler, Bio-
Rad). Samples were run in duplicate and the experiment 
was replicated 3 times. All MMTV-PyMT;ApcMin/+ samples 
plus the MMTV-PyMT;Apc+/+ solvent control were run on 
one plate for each run and MMTV-PyMT;Apc+/+ cells plus 
the MMTV-PyMT;ApcMin/+ solvent control were run on one 
plate. This allowed for comparisons between the MMTV-
PyMT;Apc+/+ control and MMTV-PyMT;ApcMin/+ cells with 
all combinations of treatments and vice versa.
Aldefluor assay 
To determine the population of TICs, we performed 
Aldefluor assays (Stem Cell Technologies, Vancouver, 
British Colombia) according to manufacturer’s 
recommendations and as previously described [12]. 
Briefly, 1 × 106 cells were plated in a 10 cm dish 
overnight prior to 24-hour treatment with A69 (10 μM). 
After A69 treatment, 2 × 105 cells were suspended in 
Aldefluor assay buffer containing ALDH substrate 
(Bodipy-Aminoacetaldehyde or BAAA), which served as 
the “test” sample. As a control, half of this sample was 
moved to a second tube where diethylaminobenzaldehyde 
(DEAB), a specific ALDH1 enzyme inhibitor was also 
added. Both samples were incubated for 60 minutes 
at 37°C. The fluorescent ALDH-expressing cells 
were detected in the green channel (515–535 nm) of a 
Cytotomics FC 500 (Beckman Coulter, Brea, CA) flow 
cytometer. Data were analyzed using FlowJo Flow 
Cytometry Data Analysis Software (Tree Star, Ashland, 
OR). The percent shift between gated events in the test 
versus control samples was calculated to give the relative 
TIC population.
Interleukin 6 ELISA 
The production of the cytokine IL-6 was measured in 
media in MMTV-PyMT;ApcMin/+ and MMTV-PyMT;Apc+/+ 
cells. 1x106 cells were plated in a 10cm plate, and after 
24 hours, media was removed and plates were washed 
with PBS. New media was added to plates and cells were 
allowed to grow for 24 hours prior to media collection and 
stored at –80°C. Enzyme linked immunosorbent assays 
(ELISA) specific for mouse IL-6 were run according 
the manufacturer’s instructions (Enzo Life Sciences, 
Farmingdale, NY). Chemiluminescence was measured on a 
SpectraMax M3 plate reader (Molecular Devices). Samples 
were run in duplicate and a 7-point standard curve was used 
to calculate concentration in pg/mL.
Statistical analysis
Student’s t-tests were used for any analysis that 
included only comparisons for MMTV-PyMT;Apc+/+ 
versus MMTV-PyMT;ApcMin/+ cells. For all other 
analyses, a two-way ANOVA was performed using 
the LS Means statement with the Proc GLM platform 
of SAS University Edition (Cary, NC) for all pre-
planned comparisons. A p-value < 0.05 was considered 
significant.
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